Verteporfin-loaded hydrogel targeting YAP-mediated MDSCs recruitment for the treatment of residual tumors after incomplete radiofrequency ablation

J. Chen, Junfeng Liu, Xiaoting Zhang, Xi Li, Jinming Fan, Shengchao Zhao, Junbin Liu, Bin Zhou, Ke ZhangTheranostics 2025 · DOI

TL;DR

This study reveals that incomplete radiofrequency ablation (iRFA) in liver cancer (HCC) activates the YAP pathway, leading to an immunosuppressive tumor microenvironment by recruiting myeloid-derived suppressor cells (MDSCs). Researchers developed a novel hydrogel that delivers verteporfin (VP), a YAP inhibitor, directly to residual tumors, effectively suppressing MDSCs and enhancing anti-tumor immunity, thereby preventing tumor recurrence.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Radiofrequency ablation (RFA) is a common treatment for early-stage HCC, but incomplete ablation (iRFA) often leads to tumor relapse and spread. This relapse is linked to an immunosuppressive tumor microenvironment that hinders the body's own anti-cancer defenses. While iRFA is known to promote this immunosuppression, the specific molecular mechanisms and effective therapeutic strategies to counteract it remain unclear. This paper aims to uncover these mechanisms and propose a novel therapeutic approach to improve outcomes after iRFA.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies: They used Hepa1-6 and Hep3B HCC cell lines to investigate the effects of heat stress (mimicking iRFA) on YAP activation and the subsequent expression of MDSC-recruiting chemokines. They also tested the efficacy of verteporfin (VP), a YAP inhibitor, in these cell models.
  • In vivo studies: A mouse model of HCC with iRFA was established. Different treatment groups received iRFA alone, iRFA with a blank hydrogel, iRFA with free VP, or iRFA with the novel VP-loaded hydrogel (QCS/TA@VP). Tumor growth, immune cell infiltration (especially MDSCs and CD8+ T cells), and survival were monitored.
  • Hydrogel Development and Characterization: A new injectable hydrogel composed of quaternized chitosan (QCS) and tannic acid (TA) was synthesized to encapsulate VP. This hydrogel was characterized for its physical properties, injectability, drug release kinetics, and biocompatibility.
  • Molecular and Cellular Analysis: Techniques like immunohistochemistry (IHC), immunofluorescence (IF), Western blotting (WB), and quantitative real-time PCR (RT-qPCR) were used to assess YAP activation, protein expression, gene expression of chemokines, and the infiltration of various immune cell populations. Flow cytometry was crucial for quantifying immune cell populations in tumors.

Datasets

Not discussed in the paper. The study relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • YAP as a central player in iRFA-induced immunosuppression: The study provides strong evidence that YAP activation is a critical mediator of the immunosuppressive microenvironment created by iRFA. This is a significant finding, linking a key oncogenic pathway to immune evasion post-treatment.
  • MDSCs are the primary culprits: The research clearly demonstrates that iRFA leads to a significant increase in MDSCs, which actively suppress anti-tumor immunity, and that YAP plays a role in recruiting these cells.
  • Targeting YAP with VP is effective: Verteporfin (VP), a known YAP inhibitor, effectively reduces MDSC infiltration and reverses immunosuppression in vitro and in vivo.
  • Hydrogel delivery is key for sustained therapy: The developed QCS/TA hydrogel provides a localized and sustained release of VP, overcoming the limitations of systemic VP administration and enhancing its therapeutic effect. This highlights the power of advanced drug delivery systems in cancer therapy.
  • Synergy between iRFA and hydrogel therapy: The QCS/TA@VP hydrogel acts as a potent adjuvant to iRFA, significantly inhibiting residual tumor growth and improving survival.

Key Results

  • YAP activation post-iRFA: Heat stress from iRFA leads to YAP dephosphorylation and nuclear translocation, activating pro-oncogenic genes like CTGF and CYR61.
  • MDSC infiltration: iRFA significantly increased MDSC infiltration in residual tumors, while decreasing cytotoxic CD8+ T cells.
  • VP efficacy: VP treatment reduced YAP nuclear localization, downregulated MDSC-associated chemokines (CXCL1, CXCL2, CXCL5, CXCL17, CCL2), and decreased MDSC infiltration in vitro and in vivo.
  • Hydrogel performance: The QCS/TA hydrogel demonstrated excellent injectability, sustained VP release over 14 days, and good biocompatibility with minimal local tissue reaction.
  • In vivo therapeutic outcomes: In the iRFA model, the QCS/TA@VP hydrogel treatment resulted in a remarkable 95% reduction in residual tumor volume compared to control groups. Complete tumor regression was observed in 16.7% of treated subjects. This treatment also significantly increased CD8+ T cell infiltration and decreased Treg infiltration.

Limitations and Future Work

The authors acknowledge several limitations:

  • Biodegradation products: While the hydrogel showed good biodegradability, the long-term systemic biosafety of its degradation products was not specifically assessed. Future work should include such evaluations.
  • In vitro release conditions: The in vitro drug release assay did not include serum proteins or proteases, which can influence release rates. Future studies will use more complex media to better predict in vivo release.
  • Animal model limitations: Subcutaneous models are convenient but do not fully replicate the complex hepatic microenvironment of HCC. The authors plan to conduct studies using rabbit orthotopic HCC/iRFA models to better assess intrahepatic hydrogel distribution, retention, and efficacy.

Despite these limitations, the study presents a promising translational strategy for improving outcomes in incompletely ablated HCC by combining targeted therapy with advanced drug delivery.

Summary updated

Abstract

<b>Background:</b> Hepatocellular carcinoma (HCC), the major form of primary liver cancer, contributes markedly to cancer-related mortality worldwide and remains a serious global health concern, particularly affecting individuals with underlying chronic liver disorders. In hepatocellular carcinoma, insufficient radiofrequency ablation (iRFA) has been reported to drive local tumor relapse and distant spread, possibly by aggravating the immunosuppressive features of the tumor microenvironment. The present work seeks to clarify the underlying pathways driving the development of an immunosuppressive milieu after RFA and to identify potential therapeutic approaches to counteract this process. <b>Methods:</b> An injectable hydrogel composed of quaternized chitosan (QCS) and tannic acid (TA) was constructed to encapsulate verteporfin (VP), a well-established photosensitizer that has been clinically applied for treating neovascular retinal disorders such as age-related macular disease. Beyond its ophthalmologic application, VP has recently been reported to display anti-tumor activity through inhibition of oncogenic regulators such as Yes-associated protein (YAP), indicating its potential utility in cancer therapy. This hydrogel formulation is designed to target residual tumor tissue post-RFA, providing localized delivery and sustained release of VP to enhance anti-tumor immune responses. <b>Results:</b> Our findings identified YAP activation as a critical mediator of immunosuppression in residual tumors following RFA. Pharmacological inhibition of YAP significantly reduced the infiltration of myeloid-derived suppressor cells (MDSCs) and effectively reversed the immunosuppressive microenvironment conditions. Furthermore, the QCS/TA hydrogel enabled sustained local release of VP, resulting in enhanced antitumor immune responses via MDSC suppression. When administered as an adjuvant therapy following suboptimal RFA, the hydrogel markedly inhibited the progression of residual tumors, highlighting its therapeutic potential in improving post-RFA outcomes. <b>Conclusion:</b> Collectively, our data suggest YAP pathway inhibition as a promising immunomodulatory strategy to complement RFA in HCC management. This work demonstrates that the QCS/TA hydrogel-based delivery system can remodel the tumor immune milieu to overcome immunosuppression and delay post-ablation tumor recurrence, supporting its potential as a translational drug delivery strategy.
BibTeX
@inproceedings{chen2025verteporfin,
  author = {J. Chen and Junfeng Liu and Xiaoting Zhang and Xi Li and Jinming Fan and Shengchao Zhao and Junbin Liu and Bin Zhou and Ke Zhang},
  title = {{Verteporfin-loaded hydrogel targeting YAP-mediated MDSCs recruitment for the treatment of residual tumors after incomplete radiofrequency ablation}},
  booktitle = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.119377},
}
Figure